At Larka, we perceive M&A and corporate transactions as an industrial and continuous process that comes with a fine-tuned transaction set of best-in-class diagnostics, frameworks, capabilities, proprietary benchmarks and other analytics tools built for the Biotech and Pharma industry.
We support our clients' overarching corporate strategies, building resiliency and delivering results on specific needs and objectives. Each deal - acquisition or divestment - must have its own strategic logic.
Our clients benefit from privileged insights and a complete mastery of the industry's intricacies, across the whole supply and value chain, cultivated over the course of nearly 30 years.
M&A, in a context of limited organic growth, requires to fine-tune the portfolio strategy through rigorous analysis, engaged leadership, supportive capabilities and focused investment. For decades, Larka has helped BioPharma companies, Contract Services Providers -CRO, CDMO, CMO - as well as equipment suppliers, identify growth opportunities and activate gradually a robust and systematic value creating approach of M&A that integrates innovative methods, fact-based on-site work, assessment of growth efforts and initiatives and investors expectations.
Most Private Equity firms do not approach the Biotech & Pharma industry with the degree of specialization it requires. Commercial due-diligence within the BioPharma space is dramatically more complex than within other universe. With nearly 30 years of experience and an unrivalled network of senior-level experts, our knowledge in the biotech & pharma industry is matchless and has made Larka the leading CDD advisor to the private equity firms within this industry. Our Commercial Due-Diligences provide extensive proprietary benchmarks across the whole drugs' supply and value chain, leading to unparalleled insights on market dynamics, competitive environment, Target's business plan, risk and opportunities.
Operational Due-Diligence provides bidders with a realistic view of the target's margin improvement potential and capabilities to convert this potential into results. Operational Due-Diligence is increasingly prominent in Private Equity industry as most acquisitions have been far from reaching full potential.
For decades, we have helped our clients capture and quantify the synergies and value creation hypotheses achievable through post-close operational improvements. This way, PE firms can properly strategize competitive purchase prices and formulate sustainable strategy to sellers and bankers.
Market opportunities, competitive advantages and organization abilities and capacities can be leveraged only if technical operations, technologies, equipment and quality systems can sustain the corporate strategy. Since 1993, Larka has been successfully conducting hundreds of Technical Due-Diligences to support acquisitions, investments, outsourcing activities or supply chain optimization. With nearly 30 years of due-diligences, Larka has become the most experienced consultancy firm in the BioPharma industry, with a unique ability to deliver Integrated Due-Diligence and full-potential vision that combines Commercial, Operational and Technical Due-Diligence.
Value creating insights within the BioPharma industry can only come from a 360-degree diligence process that aggregates strategic, commercial, technical and organizational analysis. BioPharma industry players are developing agile strategies, optimizing technical operations, and managing costs and resources in ways that are highly interdependent. Yet, most Private Equity firms do not approach due-diligences that way.
Larka has developed a unique Integrated Due-Diligence solution for Private Equity firms, built on nearly 30 years of in-depth strategic, commercial, technical and organizational diagnostics performed on hundreds of companies.
Post-acquisition plan requires a thorough preparation, value-creation initiatives, strategic planning, organizational design and communication. Most importantly, a post-acquisition plan should be designed before the deal close. For over a decade, Larka has been successfully helping its clients identify and capture the full value potential of their specific deal - merger or standalone acquisition - through structured end-to-end M&A process, tested methodologies and rigorous operating principles designed for the biotech & pharma industry.
While most executives would rather grow and create value through building than through separating, divestments have also become an equally powerful value-creating lever. A lot goes into selling a business. It is a complex process that involves a series of critical steps while keeping high standards in daily operations. It cannot be performed optimally without the support of third-party perspectives and expertise. Larka covers the entire divestment process and helps clients get the strategy and the execution right, ensuring a smooth transition towards new value creating growth opportunities and creating mutual benefits for both, sellers and buyers.
The Biotech & Pharma industry is much more complex than any other industry, with multiple technological, commercial, organizational or regulatory intricacies. Concurrently, private equity firms are demanding a more complete understanding of their prospective targets. Our Integrated Vendor Due-Diligence solution provides buyers and sellers with both, a full appreciation of the capabilities, synergies and risks involved and a full-potential vision for the business, along with the optimal post-acquisition and business plan that will justify for the buyer to pay the highest price for the asset - and for the sellers to get much higher multiples.
